Marchetti, Piero
Schulte, Anke M.
Marselli, Lorella
Schoniger, Eyke
Bugliani, Marco
Kramer, Werner
Overbergh, Lut
Ullrich, Susanne
Gloyn, Anna L.
Ibberson, Mark
Rutter, Guy
Froguel, Philippe
Groop, Leif
McCarthy, Mark I.
Dotta, Francesco
Scharfmann, Raphael
Magnan, Christophe
Eizirik, Decio L.
Mathieu, Chantal
Cnop, Miriam
Thorens, Bernard
Solimena, Michele
Article History
Received: 10 April 2019
Accepted: 24 April 2019
First Online: 13 June 2019
Duality of interest
: AMS and WK are employees of Sanofi-Aventis. GR has received research grants from Servier and is consultant for Sun Pharmaceuticals. MIMcC has received research grants from Pfizer, Merck, NovoNordisk, Abbvie, Sanofi-Aventis, Servier, Takeda, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Janssen and Roche; is consultant for Pfizer, NovoNordisk, Zoe Global, Merck and Eli Lilly; has received honorarium from Pfizer and Merck; is share-holder of Zoe Global. The remaining authors declare that there is no duality of interest associated with this manuscript.